Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus 🇨🇳 thelancet.com/journals/lance… thelancet.com/journals/lance… @TheLancet

Thank youAlex @ABiederstadt_MD for a fantastic collaboration and all the thoughtful discussions. Your ideas and contributions made our review ‘Engineered NK cells for cancer therapy’ in @CancerCell possible! #NK #Immunotherapy #CRISPR #EndCancer @MDAndersonNews

Delighted to share our Cancer Cell paper published today, co-authored by Dr. Alexander Biederstädt @ABiederstadt_MD and Dr. Rafet Basar @rftbsr9 reporting the first genome-wide CRISPR screen in primary cord blood NK and CAR NK cells. We identify key genetic checkpoints including MED12, ARIH2 and CCNC and show that their deletion enhances CAR NK cell antitumor activity in multiple tumor models. Congratulations to Alex for leading this study, to Rafet for his major contributions, and to all of our collaborators and co-authors for making this work possible. cell.com/cancer-cell/fulltex… @MDAndersonNews @kchenken #NK #CRISPR #immunotherapy #endcancer

Thank you Dr Pisters for attending today’s EAB meeting and for your inspiring vision and steadfast support. Deepest thanks also to our extraordinary EAB members: Drs Carl June, Lewis Lanier, Nicholas Huntington @Dr_Nick_Bikes , John DiPersio, Helen Heslop, Keith Sullivan, @BipinSavani and Stephan Mielke, for their time, expertise and insights. Your guidance will directly strengthen and accelerate the work of MD Anderson’s Institute for Cell Therapy Discovery and Innovation. @MDAndersonNews

Congrats to @Dr_Nick_Bikes and team on their Cancer Cell paper! CRISPR screens identify UBE2F and ARIH2 as key brakes on IL-15R signaling in NK cells. Targeting them improves NK & CAR-NK anti-tumor activity, uncovering promising targets for immunotherapy. #NKcells #CAR_NK #IL15

Many congrats Alex on this very well-deserved #societyfornaturalimmunity travel award! Your 4 years of work developing GW CRISPR screens in primary CAR-NK cells is paying off! Excited to see how your data will shape the future of NK cell therapy. @MDAndersonNews #NK2025

Hind, many congratulations on this important work & sincere thanks to the brilliant co-authors who made it possible. I’m so proud of all you’ve achieved and wish you every success as you begin your independent career. Excited to see what comes next! rdcu.be/epuy6

Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure" @PennMedicine @nejm #immunotherapy nejm.org/doi/full/10.1056/NE…

Congratulations to @ABiederstadt_MD on an outstanding presentation #AACR25, showcasing a novel platform for genome-wide CRISPR screening in primary human CAR NK cells. So proud of your achievements and excited to watch your continued impact in the field. #NKcells @MDAndersonNews

Congratulations! Looking forward to your presentation. I have no doubt it’ll be amazing!

The AACR congratulates Crystal L. Mackall, MD, FAACR, who will be honored with the 2025 AACR-@CancerResearch Lloyd J. Old Award in Cancer Immunology at #AACR25. brnw.ch/21wRUDO #AACRFellows @StanfordMed @parkerici

Brilliant work! congratulations, @may_daher and @CollaSimona and co-authors. Fascinating insight into how early NK cell dysfunction contributes to immune escape in MDS, and a compelling case for the therapeutic potential of adoptive NK cell transfer. Looking forward to seeing where this important work leads next. #NK #MDS @MDAndersonNews

Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. @CollaSimona at @MDAndersonNews in May 2025! The speaker line up is phenomenal & the science is cutting edge. Register 👇🏼 join us & RT pls mdanderson.cloud-cme.com/cou… #MDSsm

Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30 lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical demonstration of NK cell redirection using a bispecific engager. We report an ORR of 92.9% and CR of 66.7% in 42 patients with a median of 7 prior therapies and show that this approach is safe and may serve as a bridge to SCT. Excited to move forward with our next generation engineered NK cells in combination with engagers and mAbs. #CancerResearch #Immunotherapy #NKcells @MDAndersonNews

Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells @ImmunityCP cell.com/immunity/fulltext/S…